Global Pharyngeal Cancer Therapeutics Market 2019-2023 | Emergence of Pipeline Molecules to Boost Growth | Technavio

Technavio has announced its latest market research report titled global pharyngeal cancer therapeutics market 2019-2023. (Graphic: Business Wire)

LONDON--()--The global pharyngeal cancer therapeutics market is expected to post a CAGR of over 6% during the period 2019-2023, according to the latest market research report by Technavio. Request a free sample report

Pharyngeal cancer is one of the most common types of cancer as it largely attributed to the prevalence of high-risk factors such as increase in the use of tobacco, excessive alcohol consumption, increase in viral infections, and occupational exposure. Viral infections associated with the throat can lead to the development of throat cancer, including pharyngeal cancer. Moreover, individuals working in high-dose radiation environments and wood, metal, leather, textile, and petroleum industries can also develop pharyngeal cancer as they are exposed to certain chemicals, dust, or fumes. Thus, such high-risk factors are expected to fuel the growth of the market during the forecast period.

To learn more about the global trends impacting the future of market research, download free sample:

As per Technavio, the emergence of pipeline molecules, will have a positive impact on the market and contribute to its growth significantly over the forecast period. This research report also analyzes other important trends and market drivers that will affect market growth over 2019-2023.

Global Pharyngeal Cancer Therapeutics Market: Emergence of pipeline molecules

Despite the high prevalence of pharyngeal cancer, there is a lack of approved targeted therapy drugs for treatment. This is encouraging vendors to invest significantly in the development of novel therapeutics with limited side effects. For instance, Roche is developing TECENTRIQ, which is a novel PD-L1 monoclonal antibody to prevent cancer immune evasion. This molecule is being investigated in Phase lll trials in patients with adjuvant SCCHN. The filing of this molecule is expected in 2022, and it is expected to receive marketing approval by the end of the forecast period. Thus, the expected approvals of the late-stage pipeline molecules are anticipated to propel the growth of the market during the forecast period.

“Apart from the high-risk factors for pharyngeal cancer, other factors such as the presence of reimbursement and patient assistance programs, along with the advent of novel therapies are expected to boost the market growth during the forecast period,” says a senior analyst at Technavio.

Register for a free trial today and gain instant access to 10,000+ market research reports.
Technavio's SUBSCRIPTION platform

Global Pharyngeal Cancer Therapeutics Market: Segmentation Analysis

This market research report segments the global pharyngeal cancer therapeutics market by product (targeted therapy and chemotherapy) and geographical regions (North America, Europe, Asia, and ROW).

The North American region led the market in 2018, followed by Europe, Asia, and ROW respectively. During the forecast period, the North American region is expected to maintain its dominance and register the highest incremental growth due to the high prevalence of the disease and recent product approvals in the region.

Technavio’s sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more.

Request a free sample report

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

The global pharyngeal cancer therapeutics market is expected to post a CAGR of over 6% during the period 2019-2023


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200